medigraphic.com
ISSN 2007-087X (Print)
Órgano Oficial de la Sociedad Mexicana de Ortopedia Pediátrica

2018, Number 2

<< Back Next >>

Rev Mex Ortop Ped 2018; 20 (2)

Osteogenesis imperfecta: clinical presentation, classification and treatment

Vidal-Ruiz CA, Molina-Botello D, Siller-Nava JL, Calzada Vazquez-Vela C

Language: English
References: 21
Page: 86-88
PDF size: 102.76 Kb.


ABSTRACT

Osteogenesis imperfecta is a bone disorder characterized by increased bone fragility, decreased bone mass between others. It depends mostly on the prevalence of gene mutations which altered the structural architecture of collagen type I. Many classifications have been published focusing on altered genes and severity of clinical features, but the one published by Sillence in 1979 and reviewed in 2010 and 2015 is the most widely accepted. The main goal of treatment in patients with OI is to achieve improvement in rate of mineral bone density, increase mobility, diminish fracture rate, self care and functional independece associated with a high quality of life.


REFERENCES

  1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011; 7(9): 540-557.

  2. Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular abonarmilities in adults with osteogenesis imperfecta. Am Heart J. 2011; 161(3): 523-529.

  3. Steiner RD, Adsit J, Basel D. COL1A1/2-Related osteogenesis imperfecta.

  4. Chu ML, Williams CJ, Pepe G, Hirsch JL, Prockop DJ, Ramirez F. Internal deletion in a collagen gene in a perinatal lethal form of osteogenesis imperfecta. Nature. 1983; 304(5921): 78-80.

  5. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004; 363(9418): 1377-1385.

  6. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A. 2011; 155(5): 943-968.

  7. Sillence DO. Bone dysplasia. Genetic and ultrastructural aspects with reference to osteogenesis imperfecta. Ann Arbor, Michigan University Microfilms. 1980.

  8. Garretsen AJ, Cremers CW, Huygén PL. Hearing loss in relation to age in osteogenesis imperfecta type I. Ann Otol Rhinol Laryngol. 1997; 106(7 Pt 1): 575-582.

  9. Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with Osteogenesis imperfecta. Am J Med Genet. 1993; 45(2): 261-264.

  10. Bailleul-Forestier I, Berdal A, Vinckier F, de Ravel T, Fryns JP, Verloes A. The genetic basis of inherited anomalies of the teeth. Part 2: Syndromes with significant dental development. Eur J Med Genet. 2008; 51(5): 383-408.

  11. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int. 1992; 50(1): 36-41.

  12. Sillence DO, Barlow KK, Garber AP, Hall JG, Rimoin DL. Osteogenesis imperfecta type II delineation of the phenotype with reference to genetic heterogeneity. Am J Med Genet. 1984; 17(2): 407-423.

  13. Byers PH, Pyott SM. Recessively inherited forms of osteogenesis imperfecta. Annu Rev Genet. 2012; 46: 475-497.

  14. Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010; 53(1): 1-5.

  15. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Gen Part A. 2014; 164A(6): 1470-1481.

  16. Montpetit K, Palomo T, Glorieux FH, Fassier F, Rauch F. Multidisciplinary treatment of severe osteogenesis imperfecta: functional outcomes at skeletal maturity. Arch Phys Med Rehabil. 2015; 96(10): 1834-1839.

  17. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosponate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014; (7): CD005088.

  18. Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti D et al. GH in combination with bisphosponate treatment in osteogenesis imperfecta. Eur J Endocrinol. 2010; 163(3): 479-487.

  19. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone for 2 years and relevance to human safety. Toxicol Pathol. 2002; 30(3): 312-321.

  20. El-Adl G, Khalil MA, Enan A, Mostafa MF, El-Lakkany MR. Telescoping versus non-telescoping rods in the treatment of osteogenesis imperfecta. Acta Orthop Belg. 2009; 75(2): 200-208.

  21. Arundel P. Osteogenesis imperfecta. Paediatr Child Health. 2015; 25(12): 574-579.




2020     |     www.medigraphic.com